• Tiziana Life Sciences released updated clinical data from its ongoing expanded-access program of intranasal foralumab in 14 patients with non-active secondary progressive multiple sclerosis, covering results first presented in March 2025 through March 2026.
• The update showed the treatment remained well tolerated over longer use, with no new safety concerns flagged.
• Patients showed favorable trends toward stabilizing disability, with many also reporting clinically meaningful improvements in fatigue.
• The company framed the findings as supportive of further development, while noting the small expanded-access dataset limits the strength of conclusions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605190700OMX_____CNEWS_EN_GNW9722912_en) on May 19, 2026, and is solely responsible for the information contained therein.